Compare JDZG & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JDZG | AYTU |
|---|---|---|
| Founded | 2020 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.3M | 25.7M |
| IPO Year | 2023 | 2015 |
| Metric | JDZG | AYTU |
|---|---|---|
| Price | $0.12 | $2.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | ★ 9.2M | 42.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,632,080.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $44.11 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 277.47 |
| 52 Week Low | $0.11 | $0.95 |
| 52 Week High | $4.06 | $3.07 |
| Indicator | JDZG | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 39.07 | 54.76 |
| Support Level | N/A | $2.14 |
| Resistance Level | $0.57 | $2.65 |
| Average True Range (ATR) | 0.20 | 0.13 |
| MACD | -0.04 | 0.04 |
| Stochastic Oscillator | 0.66 | 71.30 |
Jiade Ltd specializes in providing one-stop comprehensive education supporting services to adult education institutions, through a wide range of software platform and auxiliary solutions. Auxiliary solutions encompass exam administration services and teaching support services throughout the entire teaching cycle. Specifically, the company offers pre-enrollment guidance on school/major selection and application strategy development, training for entrance exams, and assistance in the application process. The company also provides offline tutoring, exam administration services, guidance on graduation thesis, and social practice assistance included in the one-stop comprehensive education supporting services in the People's Republic of China.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.